Propanc Biopharma CEO Updates 2026 Outlook

Propanc Biopharma announced a shareholder update from its Chief Executive Officer and Cofounder, James Nathanielsz. "I am delighted to share an update on our recent achievements and to outline our exciting outlook for 2026. The substantial groundwork completed over the past year has positioned the Company for meaningful growth as we focus on advancing our lead clinical asset, PRP... Our management and R&D teams enter this next phase of development with a high level of confidence. Over many years, we have conducted extensive research to build a compelling scientific rationale supporting PRP's potential to make a meaningful difference for late-stage cancer patients... Since inception, Propanc has invested over $30 million to rediscover, refine, and rigorously investigate PRP as a modern cancer therapy. Our research suggests that PRP selectively targets cancer cells while leaving healthy cells unaffected, resulting in no severe or serious treatment-related side effects observed to date. While we hold strong conviction in the therapy's potential based on the accumulated evidence, our responsibility is to advance PRP through a carefully designed, efficient, and robust clinical program that prioritizes patient safety and maximizes the likelihood of success... Beyond PRP, we continue to strengthen our scientific base through longstanding research collaborations with the Universities of Jaen and Granada... Importantly, we are expanding our research into additional therapeutic indications with significant unmet medical needs... In parallel, we are advancing our preclinical program for Rec-PRP, a world-first, fully synthetic recombinant version of our lead product... Finally, we acknowledge the recent shareholder enquiries regarding our share price performance following our Nasdaq listing. Short-term market and trading dynamics can influence share price movements; however, our focus remains firmly on executing our long-term strategy and delivering meaningful clinical and scientific progress. We are confident that the year ahead holds substantial opportunity for value creation and are excited about what lies ahead."